Sage Therapeutics, Inc.
https://www.sagerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sage Therapeutics, Inc.
Sage’s Biogen-Partnered Essential Tremor Drug Fails In Phase II
For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.
Why US Payers Aren’t Reimbursing Obesity Meds
Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice